Abstract
Tumor localization with monoclonal antibodies (MAbs) is fairly successful when MAbs are recognizing glycoconjugates, epitopes being variably associated with different types of surface molecules and with high molecular weight secretory products, especially mucins. It appears that extracellular pools of antigen in tumor tissue with remnants of epithelial organization offer particularly favourable conditions for MAb access. The problem of access has been adressed by using a new monoclonal anti-mucin antibody (RA-96), which shows excellent targeting properties to tissular deposits, although the target epitope is not detectable at the surface of tumor cells.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
